Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

central precocious puberty (CPP) - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

central precocious puberty

MONDO:0019165

Also known as:CPPgonadotropin-dependant precocious pubertygonadotropin-dependent precocious puberty

Find Clinical TrialsTrials

Overview

Central precocious puberty (CPP), also referred to as gonadotropin dependent precocious puberty, is an endocrine-related developmental disease characterized by the onset of pubertal changes, with development of secondary sexual characteristics and accelerated growth and bone maturation, before the normal age of puberty (8 years in girls and 9 years in boys).

OnsetADULT

Treatments8 FDA approved

Clinical Trials4 registered · 2 recruiting

Diagnosis

Biomarker and diagnostic research for central precocious puberty has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

4 FDA-approved treatments are available for central precocious puberty, including TRIPTORELIN (TRIPTODUR, approved 2017), LEUPROLIDE ACETATE (LUPRON DEPOT-PED, approved 1993), and NAFARELIN ACETATE (SYNAREL, approved 1990). An additional 2 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

4 clinical trials registered, 2 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 2 PHASE4, 1 PHASE3. Research is sponsored by a mix of industry and academic institutions.

250 publications have been identified in PubMed for central precocious puberty. Research spans Review / Meta-Analysis (22%), Epidemiology / Natural History (22%), and Diagnostic / Biomarker (18%).

Research Type	Count	% of Total
Research summaries	46

Data assembled from 5 of 12 sources · Last updated Sep 17, 2026, 8:58 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:650063 Orphanet:759

GARD

Genetic and Rare Diseases Info Center

GARD:16546

Questions for Your Care Team

→What are the benefits and potential side effects of TRIPTODUR for managing central precocious puberty?
→Are any of the 4 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
Supprelin Injection	Histrelin acetate	Roberts Pharmaceutical Corp.	1988	1998	Designated (drug approved for other indication)
Deslorelin	Deslorelin	Roberts Pharmaceutical Corp.	1987	—	Designated

Kisho

central precocious puberty

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Central Precocious Puberty and Sjogren-Larsson Syndrome in a Child: A Rare Case Report.

central precocious puberty

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

External Resources

Orphanet

GARD

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Central Precocious Puberty and Sjogren-Larsson Syndrome in a Child: A Rare Case Report.